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tially activated by thymidine phosphorylase to 5-FU
within tumor cells. A randomized phase III clinical trial
comparing capecitabine (n  301, 1250 mg/m2/bid 

14d, q3 weeks) vs. Mayo Clinic (M)-regimen (n  301,
5-FU 425 mg/m2; LCV 20 mg/m2 d1-5, q4 weeks) re-
sulted in a superior response rate (26.6% vs. 17.9%, P 
0.013), equivalent progression-free survival (5.3 vs 4.8
months, HR (hazard ratio) 0.96), equivalent overall sur-
vival (13.2 vs 12.4 months, HR 0.91), and a superior
safety profile in terms of significantly less gastrointestinal
toxicity, neutropenia and alopecia for capecitabine. OB-
JECTIVE: To evaluate the economic consequences of oral
capecitabine vs. i.v. M-regimen administration. METHODS:
Patients were recruited from 66 centers in 8 EU-coun-
tries, Australia, New Zealand, Russia, Israel and Taiwan.
Data on number and duration of visits for drug adminis-
tration were collected during the clinical trial for all ran-
domized patients and analyzed. Cost estimates based on
publicly available statistics were used. RESULTS: For
capecitabine, one visit per cycle (every 21 days) was sched-
uled and 5 per cycle (every 28 days) for the M-regimen.
Overall, 73% of scheduled visits (for drug administra-
tion) were avoided. In all countries, with the exception of
Germany, the M-regimen was administered as an outpa-
tient treatment (96.8%–100%). In Germany 40% of all
M-regimen administrations involved overnight stays in
the hospital. Savings per patient in the range of €2,200
(UK outpatient) and €8,000 (Germany in-patient) may be
expected due to capecitabines’ oral route of administra-
tion. CONCLUSION: Oral administration of capecita-
bine substantially reduces the number of visits cancer
patients make to treating centers compared to i.v. admin-
istration (M-regimen). 73% of drug administration visits
were avoided in this phase III study. Improvements in
patient convenience and considerable savings to the
healthcare system can be realized with oral drug adminis-
tration.
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OBJECTIVE: To observe patterns of antidepressant use
and concomitant psychotropics to determine implications
for clinical prescribing practice. METHOD: Among 1.6
million members of Merck-Medco Managed Care, L.L.C.
followed continuously between 1/1/96 and 12/31/98, we
identified all patients (N  42,510) who received a new
prescription (defined as none within the prior 12 months)
for an antidepressant in 1997 (Index AD). We observed
the time between the use of other concomitant psychotro-
pics (e.g. antipsychotics(AP)/atypicals(AP-A), anxiolytics
(ANX)/buspirone(ANX-B), sedative/hypnotics (SH) and
zolipidem (SH-Z), and miscellaneous (MISC)) in the year
prior to or after the index AD prescription. RESULTS:
14, 792 (34.8%) of AD patients used a concomitant psy-
chotropic. These patients displayed a parallel pattern in
use of all classes of concomitants: 0.2–12.2% using at
least one additional class 4 months prior to, 0.3–2.0%
same day, and 0.8–3.0% 4 months after the index antide-
pressant. However, patients were more likely to receive a
traditional antipsychotic and anxiolytic prior to the in-
dex AD, and an atypical antipsychotic and buspirone af-
ter the index AD.
Concomitant % of ADpatients
Pre Index
AD
Same
Day
Post Index
AD
AP 2.3 .7 .3 1.3
AP-A 2.4 .2 .4 1.8
ANX 21.3 12.2 2.0 7.1
ANX-B 3.7 1.5 .4 1.8
MISC 2.6 .7 .3 .8
SH 5.7 3.0 .4 2.3
SH-Z 9.0 4.4 .7 3.0
CONCLUSION: Whereas we hypothesized excessive
benzodiazepine and hypnotic usage pre and post index
AD, we noted lower than expected usage. We did not ex-
pect the pattern of increased atypical antipsychotic usage
on the same day or subsequent to an index AD. All
classes of concomitant psychotropics revealed a similar
general pattern: a steady increase in the 4 months prior to
an index AD, a peak on the index AD date, and a taper-
ing over the next 4 months. We speculate that continuing
medical education of physicians may be contributing to a
decrease in the misuse of benzodiazepines and sedative/
hypnotics.
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OBJECTIVES: To assess the risk of diabetes among pa-
tients undergoing treatment with risperidone vs olanza-
pine. A series of case reports had previously associated
olanzapine use with the development of hyperglycemia,
diabetes, and diabetic ketoacidosis. METHODS: Two
cohorts totaling 34,713 patients were identified from the
Quebec Medicare database between January 1997 and
31st December 1999. One cohort consisted of patients
who had at least one prescription for olanzapine during
that period (n  19,779) and the other of patients receiv-
ing risperidone but not olanzapine (n  14,934). In ei-
ther case, patients with a diagnosis of diabetes (defined as
either a recorded ICD9 250.0 to 250.93 or a prescription
